SynthesisHeart failure reviews2022
Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis.
Synthesis in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06250257 (Effect of Bromocriptine in Dilated Cardiomyopathy in Women of Reproductive Age), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Bromocriptine in Dilated Cardiomyopathy in Women of Reproductive Age: A Hospital-Based Randomized Open Label Placebo-controlled Clinical Trial
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Bromocriptine in peripartum cardiomyopathy: A meta-analysis with trial sequential analysis.ESC heart failure · 2025Pooled it
- Outcomes of subsequent pregnancy in women with peripartum cardiomyopathy: a systematic review and meta-analysis.Open heart · 2024Pooled it
- Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis.Current problems in cardiology · 2023Pooled it
- Management of Peripartum Cardiomyopathy With and Without Bromocriptine: A Comparative Study.Cureus · 2026Article
- Trends in Initial Cardiac Function, Treatment, and Outcomes in Peripartum Cardiomyopathy.The journal of obstetrics and gynaecology research · 2026Article
- Peripartum Cardiomyopathy: Current Insights into Pathogenesis and Clinical Management: A Narrative Review.Journal of clinical medicine · 2026Review
- Clinical characteristics, echocardiographic findings, and 6-month outcomes in Ugandan women with peripartum cardiomyopathy.ESC heart failure · 2026Article
- Lactation and cardiovascular health: A comprehensive review.American heart journal plus : cardiology research and practice · 2025Review
- Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry.European heart journal · 2025Article
- Autonomic balance and cardiovascular hemodynamic function in men with prolactinoma.Frontiers in endocrinology · 2025Observational
- Outcomes of peripartum cardiomyopathy in North Africa: insights from a single-center observational study in Tunisia.BMC pregnancy and childbirth · 2024Observational
- Pharmacological interventions for peripartum cardiomyopathy.The Cochrane database of systematic reviews · 2024Article
- What Do We Know about Peripartum Cardiomyopathy? Yesterday, Today, Tomorrow.International journal of molecular sciences · 2024Review
- Disease features and management of cardiomyopathies in women.Heart failure reviews · 2024Review
- The inflammatory spectrum of cardiomyopathies.Frontiers in cardiovascular medicine · 2024Review
- Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.International journal of molecular sciences · 2023Review
- Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism.Life (Basel, Switzerland) · 2023Review
- Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening form of heart failure (HF). Bromocriptine, a dopamine D2 agonist, has been used as an adjunctive treatment for PPCM with controversial benefits. A comprehensive literature search was conducted through June 2021. We included studies comparing the outcomes of PPCM with or without bromocriptine use. Pooled risk ratio (RR) with 95% confidence intervals (CI) and I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.